Development and Validation of a Predictive Model for Diagnosing EBER-positive Lymphoma-associated Hemophagocytic Lymphohistiocytosis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2025 Mar 5

PMID 40045277

Authors

Yuhong Yin

Wenzhi Zhang

Lizhen Zhao

Ying Li

Minchun Huang

Yu Han

Xiaoyan Wu

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aims to identify distinguishing factors between EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis and non-neoplastic EBV-associated hemophagocytic lymphohistiocytosis. Additionally, we developed and validated a predictive diagnostic model based on these factors.

Methods: To evaluate the early identification of individuals with EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis versus non-neoplastic EBV-associated hemophagocytic lymphohistiocytosis, we carried out a retrospective cohort research. The medical records system included 148 individuals' diagnoses of EBV-associated hemophagocytic lymphohistiocytosis between 2015 and 2023.

Results: In this study, 148 patients were included, 75 of whom had non-neoplastic EBV-associated hemophagocytic lymphohistiocytosis and the remaining 73 had EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis. The highest AUC, with a good predictive value, was found for IL-10 > 39.87 pg/ml in separating EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis from non-neoplastic EBV-associated hemophagocytic lymphohistiocytosis. The diagnosis of EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis was influenced by platelets < 33.5*10/L, IL-6 > 20.79 pg/ml, and IFN-γ > 12.12 pg/ml as independent variables. These factors were combined with the predictive value of IL-10 > 39.87 pg/ml to establish the predictive model of the nomogram for diagnosis. The training set's and validation set's areas under the ROC curves were 0.825 and 0.812, respectively, showing that the model had good discrimination, a well-calibrated model, and a clinically valid model as indicated by the clinical decision curve.

Conclusion: The results of this study showed that the prediction model based on platelets < 33.5*10/L, IL-6 > 20.79 pg/ml, IFN-γ > 12.12 pg/ml, and IL-10 > 39.87 pg/ml could more accurately distinguish between EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis and non-neoplastic EBV-associated hemophagocytic lymphohistiocytosis. This could aid clinicians in the early detection and convenient individualization of treatment for EBV-associated hemophagocytic lymphohistiocytosis.

References

Al-Samkari H, Berliner N . Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol. 2017; 13:27-49. DOI: 10.1146/annurev-pathol-020117-043625. View

Cai L, Xing Y, Xia Y, Zhang Z, Luo Z, Tang Y . Comparative study of biomarkers for the early identification of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in infectious mononucleosis. BMC Infect Dis. 2023; 23(1):728. PMC: 10601177. DOI: 10.1186/s12879-023-08654-6. View

Wang S, Lv K, Zhou Y, Cheng X, Chen Z, Shen H . A novel prognosis-prediction model based on coagulation indicators in secondary hemophagocytic lymphohistiocytosis. Ann Hematol. 2023; 102(11):3251-3259. PMC: 10567857. DOI: 10.1007/s00277-023-05398-w. View

Aulagnon F, Lapidus N, Canet E, Galicier L, Boutboul D, Peraldi M . Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. Am J Kidney Dis. 2014; 65(6):851-9. DOI: 10.1053/j.ajkd.2014.10.012. View

Zheng M, Bao Y, Wang J, Ma Y, Yang Y, Zhang P . The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases. Hematol Oncol. 2022; 40(3):381-389. DOI: 10.1002/hon.2998. View

Henter J, Horne A, Arico M, Egeler R, Filipovich A, Imashuku S . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006; 48(2):124-31. DOI: 10.1002/pbc.21039. View

Tamamyan G, Kantarjian H, Ning J, Jain P, Sasaki K, McClain K . Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016; 122(18):2857-66. PMC: 5014667. DOI: 10.1002/cncr.30084. View

Wilson F, Berns J . Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol. 2012; 7(10):1730-9. DOI: 10.2215/CJN.03150312. View

Tangye S, Palendira U, Edwards E . Human immunity against EBV-lessons from the clinic. J Exp Med. 2017; 214(2):269-283. PMC: 5294862. DOI: 10.1084/jem.20161846. View

10.

Kim W, Montes-Mojarro I, Fend F, Quintanilla-Martinez L . Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases. Front Pediatr. 2019; 7:71. PMC: 6428722. DOI: 10.3389/fped.2019.00071. View

11.

Sano H, Kobayashi R, Tanaka J, Hashino S, Ota S, Torimoto Y . Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study. Br J Haematol. 2014; 165(6):786-92. DOI: 10.1111/bjh.12823. View

12.

Liang J, Wang L, Zhu H, Qian J, Liao H, Wu J . Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial. Haematologica. 2019; 105(1):e29-e32. PMC: 6939528. DOI: 10.3324/haematol.2019.220301. View

13.

Che F, Heng X, Zhang H, Su Q, Zhang B, Chen Y . Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10. Cancer Immunol Immunother. 2017; 66(6):717-729. PMC: 11028477. DOI: 10.1007/s00262-017-1961-7. View

14.

Lehmberg K, Sprekels B, Nichols K, Woessmann W, Muller I, Suttorp M . Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 2015; 170(4):539-49. DOI: 10.1111/bjh.13462. View

15.

Yuan S, Wang Y, Luo H, Jiang Z, Qiao B, Jiang Y . Serum soluble VSIG4 as a surrogate marker for the diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis. Br J Haematol. 2020; 189(1):72-83. DOI: 10.1111/bjh.16299. View

16.

Zhao A, Yang J, Li M, Li L, Gan X, Wang J . Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients. Front Immunol. 2022; 13:882589. PMC: 9035824. DOI: 10.3389/fimmu.2022.882589. View

17.

Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S . EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2011; 119(3):673-86. DOI: 10.1182/blood-2011-10-381921. View

18.

Coffey A, Lewis A, Marcogliese A, Elghetany M, Punia J, Chang C . A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America. Pediatr Blood Cancer. 2019; 66(8):e27798. DOI: 10.1002/pbc.27798. View

19.

Riviere S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O . Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med. 2014; 127(11):1118-1125. DOI: 10.1016/j.amjmed.2014.04.034. View

20.

Lu R, Jiang M, Chen Z, Xu X, Hu H, Zhao X . Lactate dehydrogenase 5 expression in Non-Hodgkin lymphoma is associated with the induced hypoxia regulated protein and poor prognosis. PLoS One. 2013; 8(9):e74853. PMC: 3781153. DOI: 10.1371/journal.pone.0074853. View